I think they are the same.This is from the 2010 article...

"MannKind’s IRE-1a inhibitor (MKC204) is currently undergoing the preclinical and nonclinical evaluation required to support an Investigational New Application (IND) with the U.S. Food and Drug Administration. In addition to multiple myeloma, MKC204 may have potential applications in other indications where the UPR pathway plays a key role, such as breast, brain, and pancreatic cancers; autoimmune diseases, such as rheumatoid arthritis and lupus; and neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and specific metabolic disorders.

This is from the press release...

Dr. David Bearss, Founder of Tolero, added, “BTK has already been demonstrated to be a validated clinical target in multiple disease settings. We believe that MannKind has developed a series of novel compounds with unique mechanisms of action that may lead to important treatments for cancer and autoimmune diseases, such as rheumatoid arthritis. We are excited to be a strategic partner with MannKind.”